Skip to main content
Delfa

← All trials/NCT02417103

TerminatedPhase 3

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

2

Study population

Bariatric Surgery Candidate, Obesity / overweight, Type 2 diabetes

Eligibility highlights

•BMI 35-55

Primary endpoint

•Weight reduction

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02417103
Org study IDGLP1Bariatric

Timeline

Milestones

Study first posted2015-04-15estimated
Last update posted2022-06-30actual
Study start2011-12 (month precision)
Primary completion2016-09actual (month precision)
Study completion2016-12actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Bariatric Surgery CandidateObesity / overweightType 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age77 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•BMI 35-55 Kg/m2
•Fasting Blood glucose >140mg/dl
•Planned bariatric surgery
•Diabetic Medication (Metformin, Sulfonylurea, Insuline)

Exclusion criteria

•Known hypersensitivity against Liraglutid
•Pretreatment DPP-4 Inhibitors or GLP-1 Analogue the last 3 months
•HbA1c >10%

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
1
Other (unclassified)
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

weight reduction

Time frame:4 years

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

GLP-1 Levels

Time frame:4 years

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.